Search

Your search keyword '"Ingersoll H"' showing total 16 results
Start Over Author "Ingersoll H"
16 results on '"Ingersoll H"'

4. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation

Author

Steinberg, Benjamin A., primary, Holmes, DaJuanicia N., additional, Pieper, Karen, additional, Allen, Larry A., additional, Chan, Paul S., additional, Ezekowitz, Michael D., additional, Freeman, James V., additional, Fonarow, Gregg C., additional, Gersh, Bernard J., additional, Hylek, Elaine M., additional, Kowey, Peter R., additional, Mahaffey, Kenneth W., additional, Naccarelli, Gerald, additional, Reiffel, James, additional, Singer, Daniel E., additional, Peterson, Eric D., additional, Piccini, Jonathan P., additional, Mendelson, R., additional, Nahhas, A., additional, Neutel, J., additional, Padanilam, B., additional, Pan, D., additional, Poock, J., additional, Raffetto, J., additional, Greengold, R., additional, Roan, P., additional, Saba, F., additional, Sackett, M., additional, Schneider, R., additional, Seymour, Z., additional, Shanes, J., additional, Shoemaker, J., additional, Simms, V., additional, Smiley, N., additional, Smith, D., additional, Snipes, C., additional, Sotolongo, R., additional, Staniloae, C., additional, Stoltz, S., additional, Suresh, D.P., additional, Tak, T., additional, Tannenbaum, A., additional, Turk, S., additional, Vora, K., additional, Randhawa, P., additional, Zebrack, J., additional, Silva, E., additional, Riley, E., additional, Weinstein, D., additional, Vasiliauskas, T., additional, Goldbarg, S., additional, Hayward, D., additional, Yarlagadda, C., additional, Laurion, D., additional, Osunkoya, A., additional, Burns, R., additional, Castor, T., additional, Spiller, D., additional, Luttman, C., additional, Anton, S., additional, McGarvey, J., additional, Guthrie, R., additional, Deriso, G., additional, Flood, R., additional, Fleischer, L., additional, Fierstein, J.S., additional, Aggarwal, R., additional, Jacobs, G., additional, Adjei, N., additional, Akyea-Djamson, A., additional, Alfieri, A., additional, Bacon, J., additional, Bedwell, N., additional, Berger, P., additional, Berry, J., additional, Bhagwat, R., additional, Bloom, S., additional, Boccalandro, F., additional, Capo, J., additional, Kapadia, S., additional, Casanova, R., additional, Morriss III, J.E., additional, Christensen, T., additional, Elsen, J., additional, Farsad, R., additional, Fox, D., additional, Frandsen, B., additional, Gelernt, M., additional, Gill, S., additional, Grubb, S., additional, Hall, C., additional, Harris, H., additional, Hotchkiss, D., additional, Ip, J., additional, Jaffrani, N., additional, Jones, A., additional, Kazmierski, J., additional, Waxman, F., additional, Kneller, G.L., additional, Labroo, A., additional, Jaffe, B., additional, Lebenthal, M., additional, Lee, D., additional, Lillestol, M., additional, LeClerc, K., additional, Maccaro, P., additional, Mayer, N., additional, Kozlowski, J., additional, Benjamin, S., additional, Detweiler, R., additional, Igic, P., additional, Jackson, T., additional, Pappas, J., additional, Littlefield, R., additional, Frey, A., additional, Vranian, R., additional, Long, W., additional, Grena, P., additional, Arouni, A., additional, Quinn, J., additional, Browne, K., additional, Forman, S., additional, Ebinger, M., additional, Blonder, R., additional, Snyder, H., additional, Slabic, S., additional, Williams, D., additional, Stein, R., additional, Kirkland, S., additional, Cohen, K., additional, Walthall, W., additional, Davis, K., additional, Snoddy, B., additional, Alvarado, O., additional, Leach, C., additional, Rothman, S., additional, Sharma, A., additional, Olatidoye, A., additional, AlMahameed, S., additional, Rosenthal, S., additional, Sutter, G., additional, Reiter, W., additional, Thompson, T., additional, Thew, S., additional, Kobayashi, J., additional, Williams, M., additional, Kramer, J., additional, Latif, S.A., additional, Rhee, B., additional, Adler, A., additional, Ruiz-Serrano, D., additional, Stringam, S., additional, Wolok, K., additional, Focil, A., additional, Butman, S., additional, Ingersoll, H., additional, Borge, R., additional, Al-Saghir, Y., additional, Coats, P., additional, Farris, N., additional, Shore, K., additional, Schwartz, M.B., additional, Gornick, C., additional, Eilat, P., additional, Quinlan, E., additional, Paliwal, Y., additional, Mitra, R., additional, Jingo, A., additional, Aslam, A.A., additional, Watson, R., additional, Voyce, S., additional, Turakhia, M., additional, Goytia-Leos, D., additional, Lurie, M., additional, Mallis, G., additional, Atwater, B., additional, Strobel, J., additional, Murray, J., additional, Fisher, D., additional, Atieh, M., additional, Landes, R., additional, Drabick, A., additional, Harman, E., additional, Ashcraft, B., additional, Krista, M., additional, Videlefsky, A., additional, Rivera Zayas, E., additional, and Tan, A.E., additional

Published
2020
Full Text
View/download PDF

6. THE DESIGN AND FABRICATION OF AERIAL DELIVERY SLING SUSPENSIONS FROM WOVEN NYLON WEBBING.

Author

WRIGHT AIR DEVELOPMENT CENTER WRIGHT-PATTERSON AFB OHIO, Ingersoll,H. H. , Jr, WRIGHT AIR DEVELOPMENT CENTER WRIGHT-PATTERSON AFB OHIO, and Ingersoll,H. H. , Jr

Abstract

The purpose of the study was to redesign the existing sling suspensions currently used for aerial delivery purposes in order to reduce the high cost of manufacture and to increase the strength efficiency of the sling. (Author)

Published
1954

15. Developing catalyst films of health experiences: an analysis of a robust multi-stakeholder involvement journey.

Author

Davis S, Pandhi N, Warren B, Grevious N, Crowder M, Ingersoll H, Perry E, Sussman A, and Grob R

Abstract

Background: Those whose lives are most directly impacted by health care-patients, caregivers, and frontline staff-are ideally situated to improve patient health care services and care quality. Despite a proliferation of literature on both Patient and Public Involvement (PPI) and clinical quality improvement (QI), concrete strategies regarding how to involve patients remain elusive., Aim: Research suggests catalyst films, comprised of rigorously-analyzed interview data from diverse patients about their experiences with health and health care ("catalyst films") are a promising way to bring actionable patient feedback to QI. To date, such films have been crafted primarily by researchers. This project aimed to inform the science of engagement through analyzing how deliberate PPI informed the process of creating catalyst films., Methods: PPI methods included: research team norming activities through a project charter and role delineation process; key informant interviews; participant-ambassador videotaped interviews; clinician and research focus groups; and inclusion of advisors on the research team. Content studied for the analysis presented here included team meeting notes, interview and focus group transcripts, and documentation from a facilitated discussion about team processes. These data were analyzed to determine the impact of our PPI process. Member checking verified themes and lessons learned., Results: PPI shaped team deliberations and final products in substantial ways, including: what material to include in catalyst films and the tone they should convey; multiple issues regarding representation; and our collective understanding of how catalyst films could be used in the United States. Specific discussions addressed: how to include the optimal mix of interview segments that describe experiences with those that more directly point towards care improvement strategies; and how to balance positive and negative feedback from patients about experiences with care. Team process issues included ensuring equity in involvement despite team members having differing and sometimes multiple roles that complicated power dynamics and processes., Conclusions: Multiple forms and degrees of PPI resulted in significant influence on catalyst films and companion materials. Our project thus provides proof of concept for PPI in creation of video products for QI which have traditionally been crafted by researchers. The model we developed, and document in this paper, can be adapted by others creating research-derived video products. Our findings can also inform future research on how co-designing catalyst films enhances their value for QI and the application of co-designed catalyst film use in QI. Lastly, it can guide those engaged in QI and medical education in their selection of film products focused on patient experiences., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

16. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Author

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, and Shusterman N

Subjects
Adrenergic beta-Antagonists adverse effects, Aged, Blood Pressure drug effects, Carbazoles adverse effects, Cardiac Output, Low physiopathology, Carvedilol, Chronic Disease, Dose-Response Relationship, Drug, Female, Heart Rate drug effects, Hospitalization, Humans, Male, Middle Aged, Propanolamines adverse effects, Quality of Life, Survival Analysis, Adrenergic beta-Antagonists therapeutic use, Carbazoles therapeutic use, Cardiac Output, Low drug therapy, Cardiac Output, Low mortality, Propanolamines therapeutic use, Ventricular Function, Left drug effects
Abstract

Background: We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure., Methods and Results: Three hundred forty-five subjects with mild to moderate, stable chronic heart failure were randomized to receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group). After a 2- to 4-week up-titration period, subjects remained on study medication for a period of 6 months. The primary efficacy parameter was submaximal exercise measured by two different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test. Carvedilol had no detectable effect on submaximal exercise as measured by either technique. However, carvedilol was associated with dose-related improvements in LV function (by 5, 6, and 8 ejection fraction [EF] units in the low-, medium-, and high-dose carvedilol groups, respectively, compared with 2 EF units with placebo, P < .001 for linear dose response) and survival (respective crude mortality rates of 6.0%, 6.7%, and 1.1% with increasing doses of carvedilol compared with 15.5% in the placebo group, P < .001). When the three carvedilol groups were combined, the all-cause actuarial mortality risk was lowered by 73% in carvedilol-treated subjects (P < .001). Carvedilol also lowered the hospitalization rate (by 58% to 64%, P = .01) and was generally well tolerated., Conclusions: In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose-related reductions in mortality and hospitalization rate.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results